An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.
Video content above is prompted by the following question(s):
WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis
September 26th 2024In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Read More